Abstract
The success of candidate vaccines against infectious disease depends on their ability to activate components of the immune response (innate, cellular, and/or humoral) appropriate to the correlates of protection identified for the particular pathogen. Recombinant DNA technology has provided the opportunity to rationally design vaccines based upon the identified protective antigens, and also to modulate the type and magnitude of the immune response by the incorporation of genetic adjuvants. These may include cytokines, chemokines, costimulatory molecules, or hemopoietic growth factors (see ref. 1). The choice of immunomodulatory molecule reflects the polarization of the immune response (Th1 and cell-mediated or Th2 and antibody) selected to eliminate the particular pathogen by the vaccine candidate. The presence of IL-12, IL-15, IL-18, or interferon-gamma (IFN-γ) are critical in the development of Th1 responses that are directed toward cell-mediated immunity (2), and the presence of IL-4, IL-5, and IL-10 are critical in the development of Th2 responses that are directed toward antibody production (2). For weakly immunogenic antigens, the incorporation of genes that code for pro-inflammatory cytokines (e.g., IL-1α, TNF-α, or TGF-β) or costimulatory molecules (CD80, CD86, and CD40-ligand) may provide maturation signals to antigen-presenting cells (APC) to enhance their ability to present vaccine antigens, and result in an increased adaptive immune response (3,4). More recently, cytokines and chemokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF), monocyte chemotactic proteins (MCPs) and macrophage inflammatory proteins (MIPs), have been incorporated into vaccines in lieu of their potential to increase recruitment of blood-borne dendritic cells and monocytes to interstitial sites of vaccine delivery (5).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Ryan, E. J., Daly, L. M., and Mills, H. G. (2001) Immunomodulators and delivery systems for vaccination by mucosal routes. TRENDS Biotechnol. 19, 293–304.
O’Garra, A. (1998) Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8, 275–283.
Kim, J. J., Nottingham, L. K., Wilson, D. M., Bagarazzi, M. L., Tsai, A., Morrison, L. D., et al. (1998) Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes. Vaccine 16, 1828–1835.
Kim, J. J., Yang, J. S., Dentchev, T., Dang, K., and Weiner, D. B. (2000) Chemokine gene adjuvants can modulate immune responses induced by DNA vaccines. J. Interferon Cytokine Res. 20, 487–498.
Novelli, P., Hobson, P., Barnes, A., and Klavinskis, L. S. (2000) Enhancing immunity induced by a plasmid DNA encoded antigen by co-immunisation with a MIP-3α expression vector. Immunology 101 (Suppl. 1), 12–21.
Czerkinsky, C., Anjuere, F., McGhee, J. R., George-Chandy, A., Holmgren, J., Kieny, M. P., Fujiyashi, K., Mestecky, J. F., Pierrefite-Carle, V., Rask, C., and Sun, J. B. (1999) Mucosal immunity and tolerance: relevance to vaccine development. Immunol. Rev. 170, 197–222.
Eo, S. K., Lee, S., Chun, S., and Rouse, B. T. (2001) Modulation of immunity against herpes simplex virus infection via mucosal genetic transfer of plasmid DNA encoding chemokines. J. Virol. 75, 569–578.
Chun, S., Daheshia, M., Lee, S., Eo, S. K., and Rouse B. T. (1999) Distribution fate and mechanism of immune modulation following mucosal delivery of plasmid DNA encoding IL-10. J. Immunol. 163, 2393–2402.
Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
Haines, A. M., Irvine, A. S., Mountain, A., Charlesworth, J., Farrow, N. A., Hussain, R. D., et al. (2001) CL22-a novel cationic peptide for eficient transfection of mammalian cells. Gene Ther. 8, 99–110.
Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680–685
Coligan, J. E., Kruisbecek, A. M., Margulies, D. H., Shevach, E. M., and Strober, W. (1992) Current Protocols in Immunology. John Wiley and Sons, Chapter 6.
Klavinskis, L. S., Barnfield, C., Gao, L., and Parker, S. (1999) Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J. Immunol. 162, 254–262.
He, Y., Pimenov, A. A., Nayak, J. V., Plowey, J., Faldo, L. D., and Huang, L. (2000) Intravenous injection of naked DNA encoding secreted flt3 ligand dramatically increases the number of dendritic cells and natural killer cells in vivo. Hum. Gene Ther. 11, 547–554.
Kim, J. J., Trivedi, N. N., Nottingham, L. K., Morrison, L., Tsai, A., Hu, Y., et al. (1998) Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur. J. Immunol. 28, 1089–1103.
Barouch, D. H., Santra, S., Steenbeke, T. D., Zheng, X. X., Perry, H. C., Davies, M., et al. (1998) Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J. Immunol. 161, 1875–1882.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Klavinskis, L.S., Hobson, P., Woods, A. (2003). Incorporation of Immunomodulators into Plasmid DNA Vaccines. In: Robinson, A., Hudson, M.J., Cranage, M.P. (eds) Vaccine Protocols. Methods in Molecular Medicine™, vol 87. Humana Press. https://doi.org/10.1385/1-59259-399-2:195
Download citation
DOI: https://doi.org/10.1385/1-59259-399-2:195
Publisher Name: Humana Press
Print ISBN: 978-1-58829-140-0
Online ISBN: 978-1-59259-399-6
eBook Packages: Springer Protocols